People with congenital thrombotic thrombocytopenic purpura (cTTP) face a substantial burden related to healthcare use and costs, particularly for inpatient admissions directly related to…
Thrombotic thrombocytopenic purpura
Thrombotic thrombocytopenic purpura is a rare, life-threatening blood disorder marked by dangerous clotting and low platelet counts. Prompt diagnosis and treatment are critical, and with proper care, most people recover and avoid serious complications.
While there’s no cure for immune thrombocytopenia, a range of treatments — from steroids to platelet-boosting therapies — can help manage symptoms. Choosing the right plan depends on platelet levels, bleeding risk, and individual health considerations.
Latest news
Discussion
Adding Cablivi (caplacizumab-yhdp) to standard treatment for immune-mediated thrombotic thrombocytopenic purpura (iTTP) may help protect the brain by repairing damage to the blood-brain barrier,…